A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
Clinical trial NCT01928615 · TERMINATED
Trial details
- NCT number
- NCT01928615
- Sponsor
- Hoffmann-La Roche
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-09-01
- Primary completion
- 2013-10-01
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.